JP2013517304A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013517304A5 JP2013517304A5 JP2012549215A JP2012549215A JP2013517304A5 JP 2013517304 A5 JP2013517304 A5 JP 2013517304A5 JP 2012549215 A JP2012549215 A JP 2012549215A JP 2012549215 A JP2012549215 A JP 2012549215A JP 2013517304 A5 JP2013517304 A5 JP 2013517304A5
- Authority
- JP
- Japan
- Prior art keywords
- ranges
- formulation
- weight
- amount
- naproxen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims 48
- 239000000203 mixture Substances 0.000 claims 48
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 30
- 239000002552 dosage form Substances 0.000 claims 24
- 238000000034 method Methods 0.000 claims 24
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 24
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 24
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 19
- 229960002009 naproxen Drugs 0.000 claims 19
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 19
- 229960003940 naproxen sodium Drugs 0.000 claims 16
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 claims 16
- 239000002202 Polyethylene glycol Substances 0.000 claims 13
- 229920001223 polyethylene glycol Polymers 0.000 claims 13
- 238000003756 stirring Methods 0.000 claims 12
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 11
- 229940069328 povidone Drugs 0.000 claims 11
- 230000002378 acidificating effect Effects 0.000 claims 9
- 238000012377 drug delivery Methods 0.000 claims 9
- 239000002775 capsule Substances 0.000 claims 8
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 claims 6
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 claims 6
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 claims 6
- 229960005008 doxylamine succinate Drugs 0.000 claims 6
- 238000010438 heat treatment Methods 0.000 claims 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 6
- 229960003733 phenylephrine hydrochloride Drugs 0.000 claims 6
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 claims 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
- 239000000499 gel Substances 0.000 claims 5
- 239000003002 pH adjusting agent Substances 0.000 claims 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 3
- 229920003078 Povidone K 12 Polymers 0.000 claims 3
- 229960001259 diclofenac Drugs 0.000 claims 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 3
- 229960004515 diclofenac potassium Drugs 0.000 claims 3
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 claims 3
- 229960001680 ibuprofen Drugs 0.000 claims 3
- 229960000905 indomethacin Drugs 0.000 claims 3
- 229960005306 indomethacin sodium trihydrate Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- VTGPMVCGAVZLQI-UHFFFAOYSA-M sodium;2-[4-(2-methylpropyl)phenyl]propanoate;dihydrate Chemical compound O.O.[Na+].CC(C)CC1=CC=C(C(C)C([O-])=O)C=C1 VTGPMVCGAVZLQI-UHFFFAOYSA-M 0.000 claims 3
- 238000005538 encapsulation Methods 0.000 claims 2
- 239000007903 gelatin capsule Substances 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2690488A CA2690488C (en) | 2010-01-19 | 2010-01-19 | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof |
| CA2,690,488 | 2010-01-19 | ||
| PCT/CA2011/000059 WO2011088553A1 (en) | 2010-01-19 | 2011-01-19 | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016007253A Division JP2016094462A (ja) | 2010-01-19 | 2016-01-18 | ソフトゲルカプセル化のためのナプロキセンの医薬処方およびその組合せ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013517304A JP2013517304A (ja) | 2013-05-16 |
| JP2013517304A5 true JP2013517304A5 (enExample) | 2014-03-06 |
| JP5975884B2 JP5975884B2 (ja) | 2016-08-23 |
Family
ID=44303618
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012549215A Active JP5975884B2 (ja) | 2010-01-19 | 2011-01-19 | ソフトゲルカプセル化のためのナプロキセンの医薬処方およびその組合せ |
| JP2016007253A Pending JP2016094462A (ja) | 2010-01-19 | 2016-01-18 | ソフトゲルカプセル化のためのナプロキセンの医薬処方およびその組合せ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016007253A Pending JP2016094462A (ja) | 2010-01-19 | 2016-01-18 | ソフトゲルカプセル化のためのナプロキセンの医薬処方およびその組合せ |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9480667B2 (enExample) |
| EP (2) | EP2525789B1 (enExample) |
| JP (2) | JP5975884B2 (enExample) |
| AU (1) | AU2011207061B2 (enExample) |
| CA (1) | CA2690488C (enExample) |
| DK (1) | DK2525789T3 (enExample) |
| ES (1) | ES2880813T3 (enExample) |
| HU (1) | HUE055771T2 (enExample) |
| MX (1) | MX358636B (enExample) |
| PL (1) | PL2525789T3 (enExample) |
| PT (1) | PT2525789T (enExample) |
| SI (1) | SI2525789T1 (enExample) |
| WO (1) | WO2011088553A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| RU2714323C2 (ru) * | 2014-06-04 | 2020-02-14 | ДиЭс БАЙОФАРМА ЛИМИТЕД | Фармацевтические композиции, содержащие дглк, и их применение |
| CN104083339A (zh) * | 2014-08-04 | 2014-10-08 | 人福普克药业（武汉）有限公司 | 萘普生钠软胶囊及其制备方法 |
| US10368284B2 (en) * | 2014-11-12 | 2019-07-30 | T-Mobile Usa, Inc. | Quality of experience-based handover management |
| CN113896628A (zh) | 2015-05-13 | 2022-01-07 | Ds生物制药有限公司 | 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法 |
| EP3861995A1 (en) | 2015-07-21 | 2021-08-11 | Affimune Limited | Compositions comprising 15-hepe for use in treating or preventing neurologic disease |
| KR20180094516A (ko) | 2015-12-18 | 2018-08-23 | 애피뮨 리미티드 | 15-hepe를 포함하는 조성물 및 이를 사용하는 방법 |
| US11911517B2 (en) | 2018-05-16 | 2024-02-27 | Bayer Healthcare Llc | High concentration suspension formulation for cold and flu soft gel capsule medications |
| CN109692127A (zh) * | 2019-03-15 | 2019-04-30 | 王征 | 一种密封小胶囊的制备方法 |
| BR112021021414A2 (pt) * | 2019-04-26 | 2022-02-15 | Scherer Technologies Llc R P | Composição do mini softgel de naproxeno |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| US20220233452A1 (en) * | 2021-01-25 | 2022-07-28 | R.P. Scherer Technologies, Llc | Mini softgel naproxen composition |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4443428A (en) * | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
| US5071643A (en) * | 1986-10-17 | 1991-12-10 | R. P. Scherer Corporation | Solvent system enhancing the solubility of pharmaceuticals for encapsulation |
| BR9407414A (pt) * | 1993-09-07 | 1996-11-12 | Procter & Gamble | Composições contendo um sal de aminoácido de agente antiinflamatório não-esteroide de ácido propiônico e pelo menos um descongestionante um expectorante um anti-histamina e um antitussivo |
| US5484606A (en) * | 1994-01-24 | 1996-01-16 | The Procter & Gamble Company | Process for reducing the precipitation of difficulty soluble pharmaceutical actives |
| JPH09508128A (ja) * | 1994-01-24 | 1997-08-19 | ザ、プロクター、エンド、ギャンブル、カンパニー | 難溶性医薬活性剤の溶解方法 |
| US5641512A (en) * | 1995-03-29 | 1997-06-24 | The Procter & Gamble Company | Soft gelatin capsule compositions |
| EP1049459B1 (en) * | 1998-01-20 | 2009-04-22 | Applied Analytical Industries, Inc. | Oral liquid compositions |
| US6383515B2 (en) * | 1999-05-28 | 2002-05-07 | Sawyer Maryjean | Solvent system for enhancing solubility |
| US6387400B1 (en) | 2000-08-29 | 2002-05-14 | R.P. Scherer Technologies, Inc. | Process for preparing pharmaceutical compositions for use with soft gelatin formulations |
| JP2006514119A (ja) * | 2003-02-12 | 2006-04-27 | アール アンド ピー コリア カンパニー リミテッド | 溶解率が向上した難溶性薬剤の溶媒系 |
| US20090318558A1 (en) * | 2003-02-12 | 2009-12-24 | Jae-Hwan Kim | Solvent system of hardly soluble drug with improved dissolution rate |
| US20070053868A1 (en) | 2005-03-08 | 2007-03-08 | Banner Pharmacaps, Inc. | Solvent system for enhancing the solubility of pharmaceutical agents |
| US7582679B2 (en) * | 2006-02-03 | 2009-09-01 | Pharmaceutics International Incorporated | Compositions containing solid ibuprofen concentrates and methods of making solid ibuprofen concentrates |
| US20080014274A1 (en) * | 2006-07-14 | 2008-01-17 | Wyeth | Enhanced stability phenylephrine liquid compositions |
| US20110052679A1 (en) * | 2009-08-25 | 2011-03-03 | Pharmaceutics International, Inc. | Solid naproxen concentrates and related dosage forms |
-
2010
- 2010-01-19 CA CA2690488A patent/CA2690488C/en active Active
-
2011
- 2011-01-19 DK DK11734283.2T patent/DK2525789T3/da active
- 2011-01-19 AU AU2011207061A patent/AU2011207061B2/en active Active
- 2011-01-19 PL PL11734283T patent/PL2525789T3/pl unknown
- 2011-01-19 WO PCT/CA2011/000059 patent/WO2011088553A1/en not_active Ceased
- 2011-01-19 SI SI201131992T patent/SI2525789T1/sl unknown
- 2011-01-19 EP EP11734283.2A patent/EP2525789B1/en active Active
- 2011-01-19 HU HUE11734283A patent/HUE055771T2/hu unknown
- 2011-01-19 MX MX2012008300A patent/MX358636B/es active IP Right Grant
- 2011-01-19 ES ES11734283T patent/ES2880813T3/es active Active
- 2011-01-19 US US13/574,159 patent/US9480667B2/en active Active
- 2011-01-19 EP EP21177143.1A patent/EP3909567A1/en active Pending
- 2011-01-19 PT PT117342832T patent/PT2525789T/pt unknown
- 2011-01-19 JP JP2012549215A patent/JP5975884B2/ja active Active
-
2016
- 2016-01-18 JP JP2016007253A patent/JP2016094462A/ja active Pending
- 2016-10-05 US US15/285,968 patent/US10463637B2/en active Active
-
2019
- 2019-09-26 US US16/583,903 patent/US11896566B2/en active Active
-
2023
- 2023-12-29 US US18/400,069 patent/US20240139132A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013517304A5 (enExample) | ||
| ES2562799T3 (es) | Administración a velocidad modulada de fármacos desde un comprimido de tres capas que comprende tramadol, diclofenaco, paracetamol | |
| SI2529622T1 (en) | Inhibitors of bruton's tyrosine kinase | |
| MX2020011961A (es) | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas. | |
| JP2015038155A5 (enExample) | ||
| MX2015011896A (es) | Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia. | |
| AU2016238337A1 (en) | Liquisoft capsules | |
| ES2832565T3 (es) | Composición farmacéutica que contiene celecoxib y tramadol | |
| DE602007010254D1 (de) | Feste dosierungsform mit einem wirkstoff mit unterdrücktem geschmack | |
| WO2011115969A3 (en) | Process of manufacturing a lyophilized fast dissolving, muti-phasic dosage form | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| RU2014145557A (ru) | Комбинированный состав, содержащий многокомпонентную сфероидальную таблетку (мкст), заключенную в твердую капсулу, и способ его приготовления | |
| SI2729130T1 (en) | Combined formulations of darunavir | |
| MX358636B (es) | Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas. | |
| JP2019530706A5 (enExample) | ||
| WO2007075475A3 (en) | Gastric reflux resistant dosage forms | |
| AR079174A1 (es) | Composiciones para comprimidos desintegrables oralmente de ondansetron para prevenir nauseas y vomitos | |
| JP2015514739A5 (enExample) | ||
| JP2015510928A5 (enExample) | ||
| RU2018120693A (ru) | Мягкие желатиновые капсулы с рН-независимым высвобождением | |
| CN103313704A (zh) | 高度浓缩的液态对乙酰氨基酚溶液 | |
| CN100571693C (zh) | 含有布洛芬的药物组合物 | |
| RU2015137612A (ru) | Фармацевтическая дозированная лекарственная форма в виде мягкой желатиновой капсулы, содержащая модифицированную гуаровую камедь | |
| JP2012505830A5 (enExample) | ||
| WO2011083402A3 (en) | Immediate release compositions of acid labile drugs |